文献速递血栓与止血

易栓症患者停抗凝后复发性静脉血栓栓塞:系统综述与荟萃分析

Recurrent VTE in patients with thrombophilia after stopping anticoagulation: a systematic review and meta-analysis.
PubMed 文献 · Blood Adv · 2026-01-01

该系统综述与荟萃分析纳入51项研究(34 623例患者,42.3%女性,33.5%为无诱因索引VTE),评估遗传性和获得性易栓症与停抗凝后复发性VTE的关联。结果显示APS、ATD、纯合FVL和复合杂合FVL/PTM与复发风险增加约2至3倍相关,杂合FVL或PTM增加1.5倍;PSD和PCD证据不确定。

要点

  • APS、ATD、纯合FVL和复合杂合FVL/PTM与停抗凝后复发VTE风险增加约2至3倍相关。
  • 杂合FVL或PTM突变与停抗凝后复发VTE风险增加1.5倍相关。
  • PSD和PCD与复发VTE关联的证据尚无定论。

核心结论

  • 遗传性和获得性易栓症均与停抗凝后复发性VTE风险增加相关。

研究设计与样本

  • 系统综述与荟萃分析,纳入51项随机试验和队列研究,共34 623例患者,42.3%女性,33.5%为无诱因索引VTE。

主要发现

  • APS、ATD、纯合FVL和复合杂合FVL/PTM与复发VTE风险增加约2至3倍相关。
  • 杂合FVL或PTM突变与复发VTE风险增加1.5倍相关。
  • PSD和PCD相关证据无定论;异质性和证据确定性以中等为主。

关键数值与推荐

  • 采用随机效应模型合并每100患者年的发病率、发病率比值和调整风险比。
  • 使用GRADE方法评估证据确定性。

临床怎么用

  • 对于携带APS、ATD、纯合FVL或复合杂合FVL/PTM的VTE患者,停抗凝决策需更谨慎评估复发风险。

局限性

  • 证据确定性和异质性以中等为主,PSD和PCD证据无定论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The role of thrombophilia in clinical decision-making regarding secondary venous thromboembolism (VTE) prevention is still uncertain. Therefore, we aimed to investigate the association between hereditary and acquired thrombophilia and recurrent VTE after discontinuation of anticoagulation after initial VTE treatment. We conducted a systematic review and meta-analysis to evaluate the risk of recurrent VTE in patients with and without thrombophilia including factor V Leiden (FVL) mutation, prothrombin gene G20210A mutation (PTM), antithrombin deficiency (ATD), protein C deficiency (PCD), protein S deficiency (PSD), and antiphospholipid antibody syndrome (APS). Eligible studies included randomized trials and cohort studies reporting recurrent VTE after discontinuation of anticoagulation after completion of VTE treatment. Study-level incidence rates (IR) per 100 patient-years, IR ratios, and adjusted hazard ratio were calculated or extracted and pooled using random-effects models. Certainty of evidence was assessed using the Grading of Recommendations, Assessment, Development, and Evaluation approach. A total of 51 studies (n = 34 623 patients; 42.3% female; 33.5% with unprovoked index VTE) were included. Thrombophilias, including APS, ATD, homozygous FVL, and compound heterozygous FVL/PTM, were associated with an approximately twofold to threefold increased risk of recurrent VTE, whereas heterozygous FVL or PTM mutations were associated with a 1.5-fold increased risk. Heterogeneity and the certainty in the evidence were predominantly moderate. Evidence regarding PSD and PCD was inconclusive. Both hereditary and acquired thrombophilia are associated with an increased risk of recurrent VTE after discontinuation of anticoagulation.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Vrotniakaite-Bajerciene K, Wang TF, Sabri E, et al. Recurrent VTE in patients with thrombophilia after stopping anticoagulation: a systematic review and meta-analysis. Blood Adv. 2026. PMID: 42448302. doi:10.1182/bloodadvances.2026020623

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。